Letrozole

Generic Name
Letrozole
Brand Names
Femara, Kisqali Femara Co-pack
Drug Type
Small Molecule
Chemical Formula
C17H11N5
CAS Number
112809-51-5
Unique Ingredient Identifier
7LKK855W8I
Background

Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.

Letrozole was granted FDA approval on 25 July 1997.

Indication

Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...

Associated Conditions
Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
Associated Therapies
-
Clinical Trials
Related News

A Window-of-opportunity Study of Pelareorep in Early Breast Cancer

First Posted Date
2019-09-25
Last Posted Date
2022-08-15
Lead Sponsor
Oncolytics Biotech
Target Recruit Count
26
Registration Number
NCT04102618
Locations
🇪🇸

Hospital Clínico Universitario de Valencia, Valencia, Spain

🇪🇸

Hospital La Paz, Madrid, Spain

🇪🇸

Hospital Universitario 12 de Octubre, Madrid, Spain

and more 11 locations

A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer

First Posted Date
2019-09-19
Last Posted Date
2019-09-19
Lead Sponsor
Jinming Yu
Target Recruit Count
60
Registration Number
NCT04095390
Locations
🇨🇳

Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

First Posted Date
2019-09-19
Last Posted Date
2024-05-02
Lead Sponsor
NRG Oncology
Target Recruit Count
450
Registration Number
NCT04095364
Locations
🇺🇸

Northside Hospital, Atlanta, Georgia, United States

🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

🇺🇸

Keck Medicine of USC Koreatown, Los Angeles, California, United States

and more 848 locations

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

First Posted Date
2019-08-16
Last Posted Date
2024-10-22
Lead Sponsor
Sanofi
Target Recruit Count
367
Registration Number
NCT04059484
Locations
🇺🇦

Investigational Site Number : 8040001, Kryvyi Rih, Ukraine

🇬🇷

Investigational Site Number : 3000004, Thessaloniki, Greece

🇧🇷

Hospital de Clinicas de Porto Alegre - HCPA Site Number : 0760001, Porto Alegre, Rio Grande Do Sul, Brazil

and more 106 locations

Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer

First Posted Date
2019-08-08
Last Posted Date
2021-05-03
Lead Sponsor
Northwestern University
Target Recruit Count
27
Registration Number
NCT04049227
Locations
🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

First Posted Date
2019-08-07
Last Posted Date
2021-07-20
Lead Sponsor
Shengjing Hospital
Target Recruit Count
420
Registration Number
NCT04047758
Locations
🇨🇳

Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China

🇨🇳

Liaoning Provincial People's Hospital, Shenyang, Liaoning, China

🇨🇳

Shengjing Hospital of China Medical University, Shenyang, Liaoning, China

Letrozole for Frozen Embryo Transfer (FET) in Patients With Polycystic Ovary Syndrome (PCOS)

First Posted Date
2019-06-28
Last Posted Date
2021-01-08
Lead Sponsor
CRG UZ Brussel
Registration Number
NCT04002635

Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis

Phase 2
Active, not recruiting
Conditions
Endometriosis
Ovarian Hyperstimulation
Interventions
Drug: Placebo oral tablet
Drug: Letrozole
First Posted Date
2019-06-28
Last Posted Date
2023-11-18
Lead Sponsor
University of California, San Francisco
Target Recruit Count
65
Registration Number
NCT04002141
Locations
🇺🇸

UCSF Center for Reproductive Health, San Francisco, California, United States

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

First Posted Date
2019-05-24
Last Posted Date
2024-10-11
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Target Recruit Count
31
Registration Number
NCT03962647
Locations
🇺🇸

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Breast Cancer Treatment Based on Organ-like Culture

First Posted Date
2019-04-24
Last Posted Date
2019-04-24
Lead Sponsor
Xijing Hospital
Target Recruit Count
300
Registration Number
NCT03925233
Locations
🇨🇳

JingSu, Xi'an, Shaanxi, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy